secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-114983
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q3 net loss $15.8M; YUTREPIA PH-ILD PDUFA Jan 24, 2024
---------------------------------------------------------------

- Net loss $15.8M ($0.24/sh) vs $9.1M ($0.14/sh) in Q3 2022; cash $76.2M vs $93.3M at year-end.
- Revenue $3.7M (+15% YoY) from Sandoz treprostinil injection promotion agreement.
- R&D spend up 65% to $7.4M on YUTREPIA pre-launch; G&A up 57% to $10.6M on litigation and commercial prep.
- PDUFA date for PH-ILD label expansion Jan 24, 2024; final approval delayed to Mar 31, 2024 due to Tyvaso exclusivity.
- Oral arguments in '793 patent appeal set for Dec 4, 2023; CAFC ruling could enable final YUTREPIA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/tm2329950d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer